The 10 most recent market catalysts affecting $KMTS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 92
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Kestra Medical Technologies' Q1 earnings miss, despite a sales beat, is the primary catalyst here, causing an 8.6% pre-market decline. This indicates that the market is prioritizin…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 92
Transcript: Kestra Medical Techs Q1 2027 Earnings Conference Call
Kestra Medical Techs (KMTS) announced robust Q1 2027 financial results, with a significant 60% year-over-year revenue increase and an expanded gross margin. This strong performance…
Sep 14, 2026
Corporate Catalyst
Bearish
Impact 92
Kestra Medical Techs Q1 EPS $(0.75) Misses $(0.62) Estimate, Sales $30.971M Beat $29.007M Estimate
Kestra Medical Techs (KMTS) announced its Q1 earnings, revealing a mixed financial performance. The company reported a loss of $(0.75) per share, significantly missing the analyst …
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Kestra Medical Techs Raises FY2027 Sales Guidance from $137.000M to $141.000M vs $137.023M Est
Kestra Medical Techs (KMTS) announced an upward revision to its FY2027 sales guidance, increasing it from $137 million to $141 million. This new forecast surpasses the consensus an…
Sep 11, 2026
Corporate Catalyst
Bearish
Impact 75
Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Kestra Medical Technologies (KMTS) is facing an anticipated wider Q1 loss, with analysts forecasting a loss of 62 cents per share, significantly higher than the previous year. Whil…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Initiates Coverage On Kestra Medical Techs with Overweight Rating, Announces Price Target of $30
JP Morgan's initiation of coverage on Kestra Medical Techs with an 'Overweight' rating and a $30 price target is a significant event for the company. Analyst coverage, especially f…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 55
Oppenheimer Initiates Coverage On Kestra Medical Techs with Perform Rating
Oppenheimer analyst Suraj Kalia has initiated coverage on Kestra Medical Technologies (KMTS) with a 'Perform' rating. This event is significant because new analyst coverage, especi…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Kestra Medical Techs, Raises Price Target to $32
BTIG analyst Marie Thibault maintained a 'Buy' rating on Kestra Medical Techs and raised the price target from $30 to $32. This action reflects an analyst's updated valuation and p…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
Kestra Medical Technologies Signs Five-Year, $200M Term Loan Financing
Kestra Medical Technologies (KMTS) announced a new five-year, $200 million term loan facility with Pharmakon Advisors. This is a significant event for KMTS as it provides substanti…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 85
Kestra Medical Techs Q4 EPS $(0.67) Misses $(0.59) Estimate, Sales $28.638M Beat $26.479M Estimate
Kestra Medical Techs (KMTS) announced Q4 results where their sales of $28.638 million significantly beat the analyst consensus of $26.479 million, representing a substantial 66.18%…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.